文献速递乳腺技术与安全MRPET

评估全身MRI包括弥散加权序列在高转移风险乳腺癌患者初始分期中与PET-CT的比较:一项前瞻性队列研究

Assessment of whole-body MRI including diffusion-weighted sequences in the initial staging of breast cancer patients at high risk of metastases in comparison with PET-CT: a prospective cohort study.
PubMed 文献 · Eur Radiol · 2023-08-09

本研究前瞻性纳入45例高转移风险乳腺癌女性患者,对比全身MRI(含DWI)与PET-CT在初始分期中的一致性。结果显示两种方法对转移分期几乎完全一致(k=0.862),WB-MRI对区域淋巴结、远处淋巴结、肺、肝或骨转移的准确度为91%至96%,其中2例骨转移被PET-CT遗漏。作者认为WB-MRI可能作为PET-CT的替代检查。

要点

  • WB-MRI与PET-CT对全部部位转移分期的一致性几乎完美(k=0.862),观察者间一致性极好。
  • WB-MRI检测骨转移的准确度为92%,并发现2例PET-CT漏诊的骨转移。
  • WB-MRI对原发肿瘤、区域淋巴结状态及分期的与PET-CT一致性分别为k=0.766、k=0.756、k=0.785。

核心结论

  • 含DWI的WB-MRI在高转移风险乳腺癌患者初始分期中可能是可靠且可重复的检查,尤其对骨转移,因此可能作为PET-CT的替代检查。

研究设计与样本

  • 前瞻性队列研究,纳入45例女性(年龄>18岁、浸润性乳腺癌、初始PET-CT、体能状态0-2),排除WB-MRI禁忌及乳腺癌复发者;比较WB-MRI(含DWI)与PET-CT,主要结局为远处转移诊断的一致性,次要结局包括原发肿瘤和区域淋巴结的一致性及两名放射科医师间WB-MRI判读的一致性。

诊断标准与关键数值

  • WB-MRI与PET-CT对全部部位转移分期的符合率k=0.862;原发肿瘤分期k=0.766,区域淋巴结状态k=0.756,分期k=0.785;WB-MRI检测区域淋巴结、远处淋巴结、肺、肝或骨转移的准确度为91%至96%,其中骨转移准确度为92%。

临床应用与阅片要点

  • 作者认为含DWI的WB-MRI可能作为PET-CT的替代检查用于高转移风险乳腺癌患者的初始分期,尤其对骨转移;WB-MRI判读具有极好的观察者间一致性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The aim of this study was to assess the diffusion-weighted whole-body-MRI (WBMRI) in the initial staging of breast cancer at high risk of metastases in comparison with positron emission tomography (PET)-CT.

METHODS: Forty-five women were prospectively enrolled. The inclusion criteria were female gender, age >18, invasive breast cancer, an initial PET-CT, and a performance status of 0-2. The exclusion criteria were contraindication to WB-MRI and breast cancer recurrence. The primary outcome was the concordance of WB-MRI and PET-CT in the diagnosis of distant metastases, whereas secondary outcomes included their concordance for the primary tumor and regional lymph nodes (LN), as well as the agreement of WB-MRI interpretation between two radiologists.

RESULTS: The mean age was 51.2 years with a median size of the primary tumor of 30 mm. Concordance between the two modalities was almost perfect for metastases staging, all sites included (k = 0.862), with excellent interobserver agreement. The accuracy of WB-MRI for detecting regional LN, distant LN, lung, liver, or bone metastases ranged from 91 to 96%. In 2 patients, WB-MRI detected bone metastases that were overlooked by PET-CT. WB-MRI showed a substantial agreement with PET-CT for staging the primary tumor, regional LN status, and stage (k = 0.766, k = 0.756, and k = 0.785, respectively) with a high interobserver agreement.

CONCLUSION: WB-MRI including DWI could be a reliable and reproducible examination in the initial staging of breast cancer patients at high risk of metastases, especially for bone metastases and therefore could be used as a surrogate to PET-CT.

CLINICAL RELEVANCE STATEMENT: Whole-body-MRI including DWI is a promising technique for detecting metastases in the initial staging of breast cancer at high risk of metastases.

KEY POINTS: Whole-body-MRI (WB-MRI) was effective for detecting metastases in the initial staging of 45 breast cancer patients at high risk of metastases in comparison with PET-CT. Concordance between WB-MRI and PET-CT was almost perfect for metastases staging, all sites included, with excellent interobserver agreement. The accuracy of WB-MRI for detecting bone metastases was 92%.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Hottat NA, Badr DA, Ben Ghanem M, et al. Assessment of whole-body MRI including diffusion-weighted sequences in the initial staging of breast cancer patients at high risk of metastases in comparison with PET-CT: a prospective cohort study. Eur Radiol. 2023. PMID: 37555959. doi:10.1007/s00330-023-10060-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。